Ionis Pharmaceuticals, Inc.
IONS
Key stats
- Open
- 28.07
- Day high
- 28.56
- Day low
- 27.28
- Previous close
- 28.33
- Volume
- 6.20M
- VWAP
- 27.50
- 52-week high
- 86.74
- 52-week low
- 27.28
- Market cap
- 4.72B
- Shares out
- 166.18M
- Employees
- 1,402
- Listed
- 1991
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
PHARMACEUTICAL PREPARATIONS · CARLSBAD, CA · ionis.com
Options · expiring Nov 20
Nov 12, 4:00 PM ET- Call open interest
- 857
- Put open interest
- 817
- Put/call
- 0.95
- At-the-money IV
- 33.6%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 27.50 put | 0.95 | Nov 12, 3:54 PM | 62 | 425 | 64.4% |
| 30 call | 0.25 | Nov 12, 2:47 PM | 46 | 249 | 63.8% |
| 32.50 call | 0.08 | Nov 12, 2:55 PM | 20 | 439 | 69.1% |
| 27.50 call | 0.96 | Nov 12, 3:24 PM | 15 | 167 | 33.6% |
| 30 put | 2.80 | Nov 12, 2:52 PM | 3 | 387 | 69.8% |
| 25 call | 4.00 | Nov 10, 10:44 AM | 2 | 2 | 67.7% |
Quarterly results
Massive · Nov 9, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $242.72M | $267.95M | $246.09M | $203.33M |
| Gross profit | $239.40M | $265.21M | $243.11M | $195.37M |
| Operating income | −$130.70M | −$102.29M | −$117.42M | −$214.46M |
| Net income | −$109.97M | −$114.65M | −$92.53M | −$229.39M |
| Diluted EPS | -0.66 | -0.69 | -0.56 | -1.65 |
| Operating cash flow | −$179.42M | $565.53M | −$792.82M | −$137.71M |
| Assets | $2.91B | $2.99B | $3.45B | $3.52B |
| Liabilities | $2.52B | $2.55B | $2.96B | $3.03B |
| Equity | $393.64M | $439.74M | $491.41M | $489.09M |
Technicals
Massive · Nov 12, 2026- 50-day average44.24
- 200-day average64.77
- RSI (14 days)17.2
Short interest
Massive · Oct 30, 2026- Oct 30, 202621.17M shares · 8.4 days to cover
- Oct 15, 202620.65M shares · 7.7 days to cover
- Sep 30, 202622.51M shares · 4.6 days to cover
- Sep 15, 202620.89M shares · 5.2 days to cover
News coverage
No stories about Ionis Pharmaceuticals, Inc. right now.